ZELTIQ Aesthetics, Inc.

Court Orders Clinipro LipoCryo Removal From Market in France

PLEASANTON, Calif., 2013-05-28 22:30 CEST (GLOBE NEWSWIRE) --
ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company focused on
developing and commercializing products utilizing its proprietary
controlled-cooling technology platform, today announced that it prevailed in a
major legal case. 

On May 23, 2013, the Tribunal de Grande Instance of Paris issued its ruling on
ZELTIQ's and the Massachusetts General Hospital's (MGH) request for a permanent
injunction against Clinipro's LipoCryo based on LipoCryo's infringement of a
European patent owned by MGH and globally licensed exclusively to ZELTIQ which
is utilized in ZELTIQ's CoolSculpting® System. The Tribunal ruled that the MGH
patent is valid and enforceable and that Clinipro's LipoCryo infringes the
claims in the MGH patent. The Tribunal ordered Clinipro and its distributors
immediately to stop selling, offering for sale, importing, distributing or
marketing LipoCryo in France thus removing the product from the market. 

Mark Foley, President and Chief Executive Officer said, "We continue to take an
aggressive and proactive approach in enforcing our CoolSculpting intellectual
property and brand internationally and domestically. We are very pleased with
the Tribunal's decision which further validates CoolSculpting's strong
intellectual property position. Our proprietary CoolSculpting system is
specifically engineered to monitor, deliver and maintain a precise cooling
temperature. Counterfeit systems, such as those manufactured by Clinipro, are
looking to profit on our pioneering and innovative technology with products
that do not provide physicians and patients the safety and performance results
that they have come to expect. CoolSculpting continues to be the market leader
and is the only cold-based, non-surgical fat reduction and body contouring
treatment that is FDA-cleared. With over 550,000 procedures to date worldwide,
we have unrivaled clinical experience in this area and will continue to seek to
protect our technology, physician practices, and patients from counterfeit
products." 

Mr. Foley added, "As well, we continue to defend the investments in our
registered CoolSculpting brand by aggressively pursuing those physicians that
blatantly violate our trademarks by marketing their practices as CoolSculpting
centers. We have been successful both domestically and internationally in
defending our brand and will not tolerate unauthorized usage." 

About ZELTIQ® Aesthetics, Inc.

ZELTIQ is a medical technology company focused on developing and
commercializing products utilizing its proprietary controlled-cooling
technology platform. ZELTIQ's first commercial product, the CoolSculpting
System, is designed to selectively reduce stubborn fat that may not respond to
diet or exercise. CoolSculpting is based on the scientific principle that fat
cells are more sensitive to cold than the overlying skin and surrounding
tissues. It utilizes patented technology of precisely controlled cooling to
reduce the temperature of fat cells in the treated area, which is intended to
cause fat cell elimination through a natural biological process known as
apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably and measurably
reduce the fat layer. 


         CONTACT: INVESTOR RELATIONS:
         Patrick F. Williams
         ZELTIQ, Senior Vice President and CFO
         925-474-2500
         
         Nick Laudico / Rada Milenovici
         The Ruth Group for ZELTIQ
         646-536-7030 / 7011
         
         MEDIA CONTACT:
         Shari Gold
         GOLD PR for ZELTIQ
         714-251-0375